Seong, SY Cho, NH Kwon, IC Jeong, SY 2024-01-21T15:15:14Z 2024-01-21T15:15:14Z 2021-09-04 1999-07 0019-9567 https://pubs.kist.re.kr/handle/201004/142101 Mucosal vaccination of capsular polysaccharide (PS) of Streptococcus pneumoniae and subsequent creation of the first line of immunological defense in mucosa were examined. Mucosal as well as systemic antibody responses to PS were evoked by peroral or intranasal immunization of BALB/c mice with PS-cholera toxin B subunit (CTB) conjugates entrapped in the alginate microspheres (AM). The bacterial colonization at the lung mucosa was most profoundly inhibited (<95%) by intranasal immunization with the naked conjugate (PS-CTB), The mice vaccinated orally with encapsulated conjugate [AM(PS-CTB)] showed significant reduction on the level of pneumococcal bacteremia (<99%). Eighty percent of the mice perorally immunized with AM (PS-CTB) were protected from lethal intranasal challenge with S. pneumoniae, whereas more than 60% of the mice in the other control groups died of infection. Our novel approach may prove to be important in the development of a mucosal vaccine that will provide protection of mucosal surfaces of host. English AMER SOC MICROBIOLOGY TOXIN-B-SUBUNIT IMMUNODEFICIENCY-VIRUS TYPE-1 ANTIBODY-RESPONSE POLYSACCHARIDE ANTIGENS PNEUMOCOCCAL DISEASE DEFICIENCY SYNDROME IMMUNOSENESCENCE IMMUNOGENICITY IMMUNIZATION BACTEREMIA Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae Article 10.1128/IAI.67.7.3587-3592.1999 1 INFECTION AND IMMUNITY, v.67, no.7, pp.3587 - 3592 INFECTION AND IMMUNITY 67 7 3587 3592 scie scopus 000081063800056 2-s2.0-0032968051 Immunology Infectious Diseases Immunology Infectious Diseases Article TOXIN-B-SUBUNIT IMMUNODEFICIENCY-VIRUS TYPE-1 ANTIBODY-RESPONSE POLYSACCHARIDE ANTIGENS PNEUMOCOCCAL DISEASE DEFICIENCY SYNDROME IMMUNOSENESCENCE IMMUNOGENICITY IMMUNIZATION BACTEREMIA mucosal vaccine